These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21173799)

  • 1. Out of Africa and into epigenetics: discovering reprogramming drugs.
    Jones P
    Nat Cell Biol; 2011 Jan; 13(1):2. PubMed ID: 21173799
    [No Abstract]   [Full Text] [Related]  

  • 2. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 4. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 5. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
    Gill H
    Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
    Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
    Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Azacytidine/Azacitidine.
    Müller A; Florek M
    Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.
    Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
    Leukemia; 2014 Feb; 28(2):411-3. PubMed ID: 24025691
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
    Takahashi Y; Kimura S; Okano M
    Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
    [No Abstract]   [Full Text] [Related]  

  • 10. Azacitine (vidaza) for myelodysplastic syndrome.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 13. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
    Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
    Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular target therapy for myelodysplastic syndrome].
    Morita Y; Tanaka H; Matsumura I
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
    Ogata K; Sei K; Kawahara N; Yamamoto Y
    Br J Haematol; 2020 May; 189(4):e144-e147. PubMed ID: 32130725
    [No Abstract]   [Full Text] [Related]  

  • 16. Epigenetics in humans: an overview.
    Rivera RM; Bennett LB
    Curr Opin Endocrinol Diabetes Obes; 2010 Dec; 17(6):493-9. PubMed ID: 20962634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
    D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
    Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
    [No Abstract]   [Full Text] [Related]  

  • 18. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
    Silverman LR
    Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.